Jiangsu Hengrui Medicine Co., Ltd. and Innovent Biologics, Inc. have showcased at the recent American Diabetes Association (ADA) meeting higher rates of weight loss at an earlier phase of treatment, along with improved tolerability, than some existing drugs for their novel dual incretin receptor agonists in Chinese patients who are obese or overweight without diabetes.
Key Takeaways
-
Hengrui and Innovent showcased higher rates of weight loss at an earlier phase of treatment, along with improved tolerability, in trials with their respective obesity candidates HRS9531 and mazdutide.
-
For HRS9531 6mg, the percentage reduction in body weight from baseline in its Phase II trial was 16.7% on top of placebo after 24 weeks
The positive data came from a Phase II trial with Hengrui’s dual GLP-1/GIP receptor agonist HRS9531 and the GLORY-1 Phase III study with Innovent’s dual GLP-1/GCG receptor agonist mazdutide (licensed from Eli Lilly and Company), which enrolled Chinese subjects and